MedPath

Early Abduction Splintage on Stable Hips in Infants With Developmental Dysplasia of the Hip

Conditions
Congenital Hip Dysplasia
Interventions
Device: Abduction splintage
Registration Number
NCT02885831
Lead Sponsor
University Hospital, Brest
Brief Summary

The aim of this study is to prove the improvement of pubo-femoral distance by early abduction splintage in one-month-old infants with developmental dysplasia of the hip (with a clinical stable hip but an abnormal hip ultrasonography).

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Term infants
  • Infants between 1 and 2 months of age at inclusion
  • Clinically stable hip
  • Pathological ultrasonography : pubo-femoral distance >6mm and bony rim percentage <50%
  • Non objection of the family
Exclusion Criteria
  • Clinically unstable hip
  • Normal ultrasonography
  • Neuro-orthopedic disease
  • Postural deformity of the pelvis
  • Participation refusal

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
A - Abduction splintageAbduction splintageTreatment by abduction splintage. Sonographic, clinical and radiographic surveillance. 45 patients.
Primary Outcome Measures
NameTimeMethod
Normal or abnormal hip ultrasound2 months

A normal or abnormal hip ultrasound will be base on two outcomes :

* Pubo-femoral distance (ultrasonographic measurement) : distance between the pubic bone and the cartilaginous femoral head, considered as normal if lower than 6mm.

* Bony rim percentage (ultrasonographic measurement) : percentage of the cartilaginous femoral head covered by the acetabular roof, considered as normal if higher than 50% (or equal to 50%).

* Data of pubo-femoral distance and bony rim percentage will be pooled to determine if the ultrasound is normal or not for each patient. If one out of two is abnormal, ultrasound is considered abnormal. Statistics will be based on this qualitative value : normal or abnormal ultrasound.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHRU de Brest

🇫🇷

Brest, France

© Copyright 2025. All Rights Reserved by MedPath